You are here

Phoenicia Biosciences, Inc.

Company Information
Address
45 Beaver Rd
Weston, MA 02493-1017
United States


http://www.phoeniciabiosciences.com

Information

DUNS: 808428689

# of Employees: 6


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Virus targeted therapeutic for EBV Associated Malignancies

    Amount: $991,591.00

    DESCRIPTION provided by applicant Epstein Barr virus EBV is associated with a number of human malignancies and likely plays a causal role in two endemic tumors African Burkitt lymphoma BL and ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  2. Development of a clinical hemoglobin modulator

    Amount: $999,992.00

    DESCRIPTION provided by applicant The thalassemias and sickle cell disease are serious genetic blood diseases which are WHO designated as a growing global health burden The disorders decrease ...

    STTRPhase II2014Department of Health and Human Services National Institutes of Health
  3. Topical Therapeutic to Promote Healing of Chronic Wounds

    Amount: $219,306.00

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is ...

    STTRPhase I2013Department of Health and Human Services National Institutes of Health
  4. Next Generation Therapeutics for Hemoglobinopathies

    Amount: $491,254.00

    DESCRIPTION (provided by applicant): Sickle cell disease and 2-thalassemias are mankind's most common hereditary monogenic diseases, comprise a major global health burden, and cost the US healthc ...

    STTRPhase I2012Department of Health and Human Services National Institutes of Health
  5. Virus-Targeted Therapy for Malignancies

    Amount: $288,895.00

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human malignancies for which there are presently few effective treatments. Lymphoid malignancies caused by ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  6. in vivo Studies of Clinical Stage Globin Modulators

    Amount: $304,344.00

    DESCRIPTION (provided by applicant): Inherited disorders which decrease production or alter structure of the 2-chain of hemoglobin A (2-thalassemias or sickle cell disease) are among the most common m ...

    STTRPhase I2011Department of Health and Human Services National Institutes of Health
  7. Oral Agents to Stimulate Neutrophil Production

    Amount: $350,566.00

    DESCRIPTION (provided by applicant): Phoenicia Biosciences, Inc. scientists have discovered a small family of low MW compounds (short-chain fatty acid derivatives (SCFADs) - designated Hemokines ) th ...

    STTRPhase I2010Department of Health and Human Services National Institutes of Health
  8. Development of an Oncogene-Targeted Therapeutic

    Amount: $271,227.00

    DESCRIPTION (provided by applicant): The concept of targeting cancer therapeutics towards specific mutations or abnormalities in tumor cells which are not found in normal tissues has the potential adv ...

    STTRPhase I2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government